Inogen, Inc. (NASDAQ:INGN) Shares Purchased by Barclays PLC

Barclays PLC boosted its holdings in shares of Inogen, Inc. (NASDAQ:INGN) by 72.9% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 55,508 shares of the medical technology company’s stock after purchasing an additional 23,398 shares during the quarter. Barclays PLC owned approximately 0.23% of Inogen worth $539,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. State Street Corp increased its stake in shares of Inogen by 2.8% in the third quarter. State Street Corp now owns 511,018 shares of the medical technology company’s stock worth $4,957,000 after buying an additional 14,054 shares during the last quarter. Quarry LP acquired a new position in Inogen during the 3rd quarter worth $59,000. Centiva Capital LP bought a new stake in shares of Inogen in the 3rd quarter worth about $138,000. Paloma Partners Management Co acquired a new stake in shares of Inogen in the 3rd quarter valued at about $126,000. Finally, Verition Fund Management LLC bought a new position in shares of Inogen during the third quarter worth about $106,000. 89.94% of the stock is owned by institutional investors and hedge funds.

Inogen Stock Up 0.2 %

INGN opened at $9.19 on Friday. The company’s 50-day moving average price is $9.38 and its 200 day moving average price is $9.76. Inogen, Inc. has a fifty-two week low of $5.08 and a fifty-two week high of $13.33. The firm has a market cap of $218.89 million, a price-to-earnings ratio of -4.08 and a beta of 1.02.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Inogen in a report on Friday, November 8th. StockNews.com downgraded Inogen from a “buy” rating to a “hold” rating in a report on Friday, December 20th.

Inogen Profile

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.